HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Szeps, M. Articles by Dalianis, T. Search for Related Content PubMed PubMed Citation Articles by Szeps, M. Articles by Dalianis, T. Agricola Articles by Szeps, M. Articles by Dalianis, T.

Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment

Michael Szeps^1,

Liselotte Dahlgren^1,

¹ Department of Oncology-Pathology, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden
² Department of Oto-Rhino-Laryngology, Helsinki University Hospital, Helsinki, Finland
³ Department of Oto-Rhino-Laryngology, Head and Neck Surgery, CancerCenterKarolinska, R8 : 01, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden

Correspondence
Liselotte Dahlgren
Liselotte.Dahlgren{at}cck.ki.se

The aim of this study was to identify recurrent respiratory papillomatosis patients who may benefit from interferon (IFN)- treatment and to determine the means of IFN- action. The presence of human papillomavirus (HPV) and viral load and proliferation rate in pre-, ongoing and post-treatment respiratory papillomatosis biopsies were examined retrospectively in 25 patients, 18 of whom were IFN- treated and seven of whom were IFN- non-treated. Using PCR, HPV was found to be present in 20/25 respiratory papillomatosis patients and HPV type was determined for 18/25 patients (12 HPV6 and six HPV11). Eighteen of the patients were treated with IFN-, 14 of whom were HPV positive (eight HPV6, five HPV11 and one undefined HPV). Response to IFN- therapy was observed in 12 patients (7/8 HPV6, 3/5 HPV11, 1/1 undefined HPV and 1/4 HPV negative), while six patients (1/8 HPV6, 2/5 HPV11 and 3/4 HPV negative) did not respond to therapy. Viral load, determined by quantitative real-time PCR (between 0·03 and 533 HPV copies per cell), and proliferation rate, determined as the percentage of Ki-67-positive cells (between 8 and 54 %), were similar in IFN--treated and non-treated patients and were generally unaffected by IFN- treatment. In summary, most (12/18) IFN--treated patients responded to therapy. Moreover, there was a tendency for patients with HPV6-positive (7/8) respiratory papillomatosis to respond more frequently to IFN- therapy than patients with HPV11 (3/5) or HPV-negative (1/4) respiratory papillomatosis. Finally, the presence of HPV and viral load and proliferation in respiratory papillomatosis biopsies was similar in patients treated or not with IFN- and were in general unaffected by IFN- treatment.

These authors contributed equally to this work.